{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T06:27:49Z","timestamp":1786429669691,"version":"build-2736575974"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Iparomlimab and tuvonralimab (QL1706) is a MabPair product consisting of PD-1 and CTLA-4 monoclonal antibodies. This single-arm, multicenter, phase 2 study assessed the safety and efficacy of first-line QL1706 plus etoposide and carboplatin (EC) for extensive-stage small cell lung cancer (ES-SCLC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with ES-SCLC received QL1706 plus EC every 3 weeks for 4\u20136 cycles, followed by QL1706 maintenance therapy until disease progression. Primary endpoint was safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 40 patients enrolled, all patients experienced at least one treatment-related adverse event (TRAE). Most TRAEs were hematologic toxicities. Nine patients (22.5%) experienced immune-related adverse events, mostly grade 1\u20132, with a median time from treatment to the first irAE of 3.1 months (range 0.1\u201311.0) with a median duration of the irAEs of 1.3 months (range 0.1\u201310.7). Grade 3 irAEs occurred in 2 (5.0%) patients, one case each for rash and vomiting. No TRAEs leading to death or treatment discontinuation occurred. In 38 patients evaluable for efficacy, the confirmed objective response rate was 92.1% (95% confidence interval [CI] 78.6\u201398.3). Median progression-free survival (PFS) and overall survival (OS) were 6.0 months (95% CI 5.4\u20138.3) and 15.8 months (95% CI 11.4\u201320.0), respectively. In exploratory analyses, the median OS was 20.5 months (95% CI 11.4\u2013not evaluable) in patients with a good lung immune prognostic index status and 19.7 months (95% CI 11.4\u201322.5) in patients with a combined positive score &amp;lt;1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>QL1706 plus EC was well-tolerated and showed promising anti-tumor activity and survival benefit in first-line treatment for ES-SCLC, and warranted further validation in larger scale phase 3 studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1879524","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T05:35:12Z","timestamp":1786426512000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and efficacy of first-line iparomlimab and tuvonralimab (QL1706) plus carboplatin and etoposide in patients with extensive-stage small cell lung cancer: an open-label, single-arm, phase 2 trial (DUBHE-L-209)"],"prefix":"10.3389","volume":"17","author":[{"given":"Yun","family":"Fan","sequence":"first","affiliation":[{"name":"Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runxiang","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Yunnan Cancer Hospital","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuhong","family":"Min","sequence":"additional","affiliation":[{"name":"Department of Tumor Radiotherapy, Anhui Chest Hospital","place":["Hefei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiwen","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Chongqing University Cancer Hospital","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Harbin Medical University Cancer Hospital","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqiu","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, The First Affiliated Hospital of Zhengzhou University","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Second Affiliated Hospital of Anhui Medical University","place":["Hefei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huayuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Qilu Pharmaceutical Co., Ltd.","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Qilu Pharmaceutical Co., Ltd.","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhehai","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Shandong Cancer Hospital","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.0560","article-title":"Small cell lung cancer: a review","volume":"333","author":"Kim","year":"2025","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21785","article-title":"Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions","volume":"73","author":"Megyesfalvi","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00224-8","article-title":"Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (Capstone-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Wang","year":"2022","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (Caspian): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.16464","article-title":"Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the Astrum-005 randomized clinical trial","volume":"328","author":"Cheng","year":"2022","journal-title":"JAMA"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.03.008","article-title":"Tislelizumab plus platinum and etoposide versus placebo plus platinum and etoposide as first-line treatment for extensive-stage SCLC (Rationale-312): a multicenter, double-blind, placebo-controlled, randomized, phase 3 clinical trial","volume":"19","author":"Cheng","year":"2024","journal-title":"J Thorac Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1001\/jamaoncol.2024.5019","article-title":"Toripalimab plus chemotherapy as a first-line therapy for extensive-stage small cell lung cancer: the phase 3 Extentorch randomized clinical trial","volume":"11","author":"Cheng","year":"2025","journal-title":"JAMA Oncol"},{"key":"B10","article-title":"Chinese Society of Clinical Oncology (Csco) guidelines for diagnosis and treatment of small cell lung cancer[M","volume-title":"Chinese Society of Clinical Oncology (Csco) Guidelines for Diagnosis and Treatment of Small Cell Lung Cancer[M]","year":"2025"},{"key":"B11","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41392-024-02115-5","article-title":"A multicenter, randomized, double-blind, placebo-controlled phase 3 study of socazolimab or placebo combined with carboplatin and etoposide in the first-line treatment of extensive-stage small cell lung cancer","volume":"10","author":"Chen","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100408","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from Caspian","volume":"7","author":"Paz-Ares","year":"2022","journal-title":"ESMO Open"},{"key":"B13","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1002\/cac2.70032","article-title":"First-line serplulimab plus chemotherapy in extensive-stage small-cell lung cancer: updated results and biomarker analysis from the Astrum-005 randomized clinical trial","volume":"45","author":"Cheng","year":"2025","journal-title":"Cancer Commun (Lond)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/s1470-2045(20)30539-8","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (Caspian): updated results from a randomised, controlled, open-label, phase 3 trial","volume":"22","author":"Goldman","year":"2021","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s43018-025-00992-5","article-title":"The current and emerging immunotherapy paradigm in small-cell lung cancer","volume":"6","author":"Qin","year":"2025","journal-title":"Nat Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/ijc.33415","article-title":"Targeting CTLA-4 in cancer: is it the ideal companion for PD-1 blockade immunotherapy combinations","volume":"149","author":"De Silva","year":"2021","journal-title":"Int J Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s13046-019-1259-z","article-title":"Combination of CTLA-4 and PD-1 blockers for treatment of cancer","volume":"38","author":"Rotte","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1821218116","article-title":"Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies","volume":"116","author":"Wei","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"B19","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41392-025-02252-5","article-title":"Harnessing local and system immune profiling delineating differential responders to first-line sintilimab (anti-PD-1 antibody) combined with chemotherapy in extensive-stage small cell lung cancer: an exploratory biomarker analysis of a phase II study","volume":"10","author":"Xie","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.697865","article-title":"Prognostic value of the pretreatment lung immune prognostic index in advanced small cell lung cancer patients treated with first-line PD-1\/PD-L1 inhibitors plus chemotherapy","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.05.042","article-title":"Improved prognosis and increased tumor-infiltrating lymphocytes in patients who have SCLC with neurologic paraneoplastic syndromes","volume":"14","author":"Iams","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-024-03690-3","article-title":"Lung immune prognostic index (LIPI) as a prognostic factor in patients with extensive-stage small cell lung cancer treated with first-line chemoimmunotherapy","volume":"27","author":"Herranz-Bayo","year":"2025","journal-title":"Clin Transl Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13045-023-01445-1","article-title":"First-in-human phase I\/Ib study of QL1706 (PSB205), a bifunctional PD1\/CTLA4 dual blocker, in patients with advanced solid tumors","volume":"16","author":"Zhao","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2025.101459","article-title":"260p safety of long-term treatment of iparomlimab and tuvonralimab (QL1706) in phase I trial","volume":"28","author":"Zhang","year":"2025","journal-title":"Immuno-Oncol Technol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102396","article-title":"Updated efficacy and predictive biomarkers of QL1706, a bifunctional PD-1\/CTLA-4 dual blocker in advanced solid tumors-a phase 1\/1b study","volume":"6","author":"Ma","year":"2025","journal-title":"Cell Rep Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.4771","article-title":"Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer","volume":"4","author":"Mezquita","year":"2018","journal-title":"JAMA Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-025-01728-9","article-title":"Safety of long-term treatment of iparomlimab and tuvonralimab (QL1706) in phase I trial","volume":"2025","author":"Zhang","year":"2025","journal-title":"Ann Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.6362","article-title":"Proportion of never smokers among men and women with lung cancer in 7 US states","volume":"7","author":"Siegel","year":"2021","journal-title":"JAMA Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jtho.2020.10.002","article-title":"Camrelizumab plus apatinib in extensive-stage SCLC (Passion): a multicenter, two-stage, phase 2 trial","volume":"16","author":"Fan","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114048","article-title":"Validation of the lung immune prognostic index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma","volume":"204","author":"Carril-Ajuria","year":"2024","journal-title":"Eur J Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jtho.2024.09.1439","article-title":"Long-term survival outcomes with first-line nivolumab plus ipilimumab-based treatment in patients with metastatic NSCLC and tumor programmed death-ligand 1 lower than 1%: a pooled analysis","volume":"20","author":"Peters","year":"2025","journal-title":"J Thorac Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/s41419-024-07191-7","article-title":"PD-L2 of tumor-derived exosomes mediates the immune escape of cancer cells via the impaired T cell function","volume":"15","author":"Liu","year":"2024","journal-title":"Cell Death Dis"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.immuni.2019.11.003","article-title":"PD-L1:CD80 cis-heterodimer triggers the co-stimulatory receptor CD28 while repressing the inhibitory PD-1 and CTLA-4 pathways","volume":"51","author":"Zhao","year":"2019","journal-title":"Immunity"},{"key":"B36","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.ccell.2018.04.001","article-title":"Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer","volume":"33","author":"Hellmann","year":"2018","journal-title":"Cancer Cell"},{"key":"B37","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1146\/annurev-immunol-042617-053402","article-title":"Cancer neoantigens","volume":"37","author":"Schumacher","year":"2019","journal-title":"Annu Rev Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1879524\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T05:35:14Z","timestamp":1786426514000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1879524\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":37,"alternative-id":["10.3389\/fimmu.2026.1879524"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1879524","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"article-number":"1879524"}}